All authors will receive specific training at PRISMA-P before the implementation of the study. Review process will be independently conducted by 2 authors, using blinding to reduce bias. Disagreements will be resolved first by discussion and then by consulting a third author for arbitration. Endnote X7 will be used to manage and screen literature. RCTs that are duplicative and do not meet the eligibility criteria will be removed. Details of literature screening process is shown in Figure Figure11.

Flow diagram for study selection.

Then, Excel 2011 software will be used to extract relevant data. The relevant information that needs to be extracted is as follows:

basic information: title, the first author's name, year of publication;

study characteristics: interventions, course of treatment, duration;

subjects characteristics: sample size, gender, age, and underlying disease;

outcomes and specific adverse reactions.

When there is uncertain information in included studies, the final decision will be made through discussion among team members.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.